Skip to main content
SpringerLink
Log in

Non-small Cell Lung Cancer

  • Chapter
  • First Online:
International Manual of Oncology Practice

Abstract

Non-small cell lung cancer (NSCLC) is most common cause of cancer death in the world. Early detection, diagnosis and treatments are the essential strategies for increased overall survival of patients. Recently, staging of NSCLC is updated to 8th edition of TNM staging for NSCLC issued by the IASLC which affects to overall survival and treatment methods. This chapter include the incidence and risk factors of lung cancer, screening for lung cancer, diagnostic investigation, pathology, stage, and current treatment modalities in each stage of disease. There are many issues in term of multimodality treatments including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AATS:

American Association for Thoracic Surgery

ACCP:

American College of Chest Physicians

ACS:

American Cancer Society

ALK:

Anaplastic Lymphoma Kinase

ASCO:

American Society of Clinical Oncology

BSC:

Best Supportive Care

CCRT:

Concurrent Chemoradiotherapy

CI:

Confidence Interval

CMS:

Centers for Medicare & Medicaid Services

COPD:

Chronic Obstructive Pulmonary Disease

DFS:

Disease-Free Survival

EBUS-NA:

Endobronchial Ultrasound Needle Aspiration

EGFR:

Epidermal Growth Factor Receptor

ESMO:

European Society for Medical Oncology

FEV1:

Forced Expiratory Volume in 1 second

IASLC:

International Association Study of Lung Cancer

IV:

Intravenous

LEC:

Large Cell Carcinoma

LN:

Lymph Node

LOS:

Length of Hospital Stay

L-SND:

Lobe-Specific Node Dissection

LUL:

Left Upper Lobe

MLN:

Mediastinal Lymph Node

MS:

Median Survival

NCCN:

National Comprehensive Cancer Network

NSCLC:

Non-small Cell Lung Cancer

OS:

Overall Survival

PFS:

Progression-Free Survival

QOL:

Quality of Life

RCT:

Randomized Controlled Trial

RML:

Right Middle Lobe

RR:

Response Rate

RT:

Radiotherapy

RUL:

Right Upper Lobe

SABR:

Stereotactic Ablative Radiotherapy

SBRT:

Stereotactic Body Radiotherapy

SCC:

Small Cell Carcinoma

SCRT:

Sequential Chemoradiotherapy

SLND:

Systematic Lymph Node Dissection

SLNS:

Systematic Lymph Node Sampling

SQCC:

Squamous Cell Carcinoma

TBNA:

Transbronchial Needle Aspiration

TKI:

Tyrosine Kinase Inhibitor

TTNA:

Transthoracic Needle Aspiration

USPSTF:

US Preventive Services Task Force

VATS:

Video-assisted Thoracoscopic Surgery

References

  1. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30

    Article  PubMed  Google Scholar 

  2. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C et al (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 28(5):1117–1123

    Article  CAS  PubMed  Google Scholar 

  3. Australian Institute of H, Welfare (2013) Cancer in Australia: actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac J Clin Oncol 9(3):199–213

    Article  Google Scholar 

  4. Sankaranarayanan R, Ramadas K, Qiao YL (2014) Managing the changing burden of cancer in Asia. BMC Med 12:3

    Article  PubMed  PubMed Central  Google Scholar 

  5. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132

    Article  PubMed  Google Scholar 

  6. Steinmaus C, Ferreccio C, Acevedo J, Yuan Y, Liaw J, Duran V et al (2014) Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomark Prev 23(8):1529–1538

    Article  CAS  Google Scholar 

  7. Beveridge R, Pintos J, Parent ME, Asselin J, Siemiatycki J (2010) Lung cancer risk associated with occupational exposure to nickel, chromium VI, and cadmium in two population-based case-control studies in Montreal. Am J Ind Med 53(5):476–485

    PubMed  Google Scholar 

  8. Matrat M, Guida F, Mattei F, Cenee S, Cyr D, Fevotte J et al (2016) Welding, a risk factor of lung cancer: the ICARE study. Occup Environ Med 73(4):254–261

    Article  PubMed  Google Scholar 

  9. Peters S, Kromhout H, Olsson AC, Wichmann HE, Bruske I, Consonni D et al (2012) Occupational exposure to organic dust increases lung cancer risk in the general population. Thorax 67(2):111–116

    Article  PubMed  Google Scholar 

  10. Sha A (2016) 37P Domestic cooking fuel as a risk factor for lung cancer in women: a case control study. J Thorac Oncol 11(4 Suppl):S70–S71

    Article  Google Scholar 

  11. Olsson AC, Vermeulen R, Schuz J, Kromhout H, Pesch B, Peters S et al (2017) Exposure-response analyses of asbestos and lung cancer subtypes in a pooled analysis of case-control studies. Epidemiology 28(2):288–299

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kim CH, Lee YC, Hung RJ, McNallan SR, Cote ML, Lim WY et al (2014) Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO). Int J Cancer 135(8):1918–1930

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Masjedi MR, Naghan PA, Taslimi S, Yousefifard M, Ebrahimi SM, Khosravi A et al (2013) Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration 85(2):112–118

    Article  PubMed  Google Scholar 

  14. Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K (2014) Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol 5(4):660–666

    Article  PubMed  PubMed Central  Google Scholar 

  15. Liu Y, Zhu M, Geng J, Ban C, Zhang S, Chen W et al (2017) Incidence and radiologic-pathological features of lung cancer in Idiopathic pulmonary fibrosis. Clin Respir J 12(4):1700–1705

    Article  CAS  PubMed  Google Scholar 

  16. Gawelek E, Drozdzowska B, Fuchs A (2017) Radon as a risk factor of lung cancer. Przegl Epidemiol 71(1):90–98

    PubMed  Google Scholar 

  17. Torres-Duran M, Ruano-Ravina A, Parente-Lamelas I, Leiro-Fernandez V, Abal-Arca J, Montero-Martinez C et al (2014) Lung cancer in never-smokers: a case-control study in a radon-prone area (Galicia, Spain). Eur Respir J 44(4):994–1001

    Article  PubMed  Google Scholar 

  18. Lin H, Huang YS, Yan HH, Yang XN, Zhong WZ, Ye HW et al (2015) A family history of cancer and lung cancer risk in never-smokers: a clinic-based case-control study. Lung Cancer 89(2):94–98

    Article  PubMed  Google Scholar 

  19. Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST et al (2012) HIV as an independent risk factor for incident lung cancer. AIDS 26(8):1017–1025

    Article  PubMed  Google Scholar 

  20. Kaluzna EM, Rembowska J, Ziolkowska-Suchanek I, Swiatek-Koscielna B, Gabryel P, Dyszkiewicz W et al (2015) Heterozygous p.I171V mutation of the NBN gene as a risk factor for lung cancer development. Oncol Lett 10(5):3300–3304

    Article  PubMed  PubMed Central  Google Scholar 

  21. Fan J, Zhang W, Lei C, Qiao B, Liu Q, Chen Q et al (2015) Vascular endothelial growth factor polymorphisms and lung cancer risk. Int J Clin Exp Med 8(4):6406–6411

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Ezzeldin N, El-Lebedy D, Darwish A, El-Bastawissy A, Shalaby AE (2015) Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer. Contemp Oncol (Pozn) 19(6):441–445

    CAS  Google Scholar 

  23. Yamamoto Y, Kiyohara C, Suetsugu-Ogata S, Hamada N, Nakanishi Y (2017) Biological interaction of cigarette smoking on the association between genetic polymorphisms involved in inflammation and the risk of lung cancer: a case-control study in Japan. Oncol Lett 13(5):3873–3881

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S et al (2007) NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev 8(1):103–108

    PubMed  Google Scholar 

  25. Fan H, Yu H, Deng H, Chen X (2014) Transforming growth factor-beta1 rs1800470 polymorphism is associated with lung cancer risk: a meta-analysis. Med Sci Monit 20:2358–2362

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wang X, Ma K, Chi L, Cui J, Jin L, Hu JF et al (2016) Combining telomerase reverse transcriptase genetic variant rs2736100 with epidemiologic factors in the prediction of lung cancer susceptibility. J Cancer 7(7):846–853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Qiao Q, Hu W (2013) The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung 191(4):369–377

    Article  CAS  PubMed  Google Scholar 

  28. Cancer Genome Atlas Research N (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550

    Article  CAS  Google Scholar 

  29. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260

    Article  PubMed  Google Scholar 

  30. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339–346

    Article  CAS  PubMed  Google Scholar 

  31. Inamura K, Ninomiya H, Ishikawa Y, Matsubara O (2010) Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med 134(1):66–72

    CAS  PubMed  Google Scholar 

  32. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T et al (2009) Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 63(2):235–240

    Article  PubMed  Google Scholar 

  33. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18(3):378–381

    Article  CAS  PubMed  Google Scholar 

  34. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T et al (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18(3):375–377

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tantraworasin A, Lertprasertsuke N, Kongkarnka S, Euathrongchit J, Wannasopha Y, Saeteng S (2014) Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non-small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. Asian Pac J Cancer Prev 15(7):3057–3063

    Article  PubMed  Google Scholar 

  36. Inamura K (2017) Lung Cancer: understanding its molecular pathology and the 2015 WHO Classification. Front Oncol 7:193

    Article  PubMed  PubMed Central  Google Scholar 

  37. Yatabe Y, Mitsudomi T, Takahashi T (2002) TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 26(6):767–773

    Article  PubMed  Google Scholar 

  38. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409

    Article  Google Scholar 

  39. Ost DE, Yeung SC, Tanoue LT, Gould MK (2013) Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e121S–e141S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arreyakajohn N, Kasemsarn C, Patumanond J (2013) Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. Cancer Manag Res 5:77–84

    Article  PubMed  PubMed Central  Google Scholar 

  41. Fernandez-Ruiz M, Aranda-Arcas JL, Alonso-Navas F, Guerra-Vales JM (2007) Cardiac tamponade as initial clinical manifestation of a non-small cell lung cancer. Rev Clin Esp 207(11):587–589

    Article  CAS  PubMed  Google Scholar 

  42. Marcos PJ, Rodriguez-Lorenzo A (2013) Sternal mass presenting as a first manifestation of lung cancer. Am J Med Sci 346(5):420

    Article  PubMed  Google Scholar 

  43. Singh N, Kulkarni P, Aggarwal AN, Rai Mittal B, Gupta N, Behera D et al (2012) Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature. Medicine (Baltimore) 91(4):179–194

    Article  Google Scholar 

  44. Sancho del Val L, Diez Redondo P, Ruiz-Zorrilla Lopez R, Lorenzo Pelayo S, Herranz Bachiller MT, Alcaide Suarez N et al (2012) Upper gastrointestinal bleeding as the first manifestation of lung cancer. Gastroenterol Hepatol 35(10):726–727

    Article  PubMed  Google Scholar 

  45. Rakusic N, Baricevic D, Samarzija M, Jakopovic M, Baricevic M (2012) Acquired rhinophyma as a paraneoplastic manifestation of non-small cell lung cancer. Wien Klin Wochenschr 124(7–8):276–277

    Article  PubMed  Google Scholar 

  46. Mohammad K, Sadikot RT (2009) Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer. South Med J 102(6):665–667

    Article  PubMed  Google Scholar 

  47. Oda S, Awai K, Funama Y, Utsunomiya D, Yanaga Y, Kawanaka K et al (2010) Detection of small pulmonary nodules on chest radiographs: efficacy of dual-energy subtraction technique using flat-panel detector chest radiography. Clin Radiol 65(8):609–615

    Article  CAS  PubMed  Google Scholar 

  48. Pretreatment evaluation of non-small-cell lung cancer (1997) The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 156(1):320–332

    Article  Google Scholar 

  49. Mayo JR, Aldrich J, Muller NL (2003) Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 228(1):15–21

    Article  PubMed  Google Scholar 

  50. Hendee WR, O’Connor MK (2012) Radiation risks of medical imaging: separating fact from fantasy. Radiology 264(2):312–321

    Article  PubMed  Google Scholar 

  51. Benko A, Fraser-Hill M, Magner P, Capusten B, Barrett B, Myers A et al (2007) Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J = Journal l’Association canadienne des radiologistes 58(2):79–87

    PubMed  Google Scholar 

  52. Ohno Y, Koyama H, Lee HY, Yoshikawa T, Sugimura K (2016) Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for lung cancer staging. J Thorac Imaging 31(4):215–227

    Article  PubMed  Google Scholar 

  53. Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA et al (2000) Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 3(6):223–230

    Article  PubMed  Google Scholar 

  54. Kligerman S, Digumarthy S (2009) Staging of non-small cell lung cancer using integrated PET/CT. AJR 193(5):1203–1211

    Article  PubMed  Google Scholar 

  55. Kapoor V, McCook BM, Torok FS (2004) An introduction to PET-CT imaging. Radiographics 24(2):523–543

    Article  PubMed  Google Scholar 

  56. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA (2004) The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78(3):1017–1023. discussion -23

    Article  PubMed  Google Scholar 

  57. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H et al (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229(2):526–533

    Article  PubMed  Google Scholar 

  58. Vansteenkiste JF, Stroobants SS (2006) PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol 1(1):71–73

    Article  PubMed  Google Scholar 

  59. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39–51

    Article  PubMed  Google Scholar 

  60. Van Schil PE, Sihoe AD, Travis WD (2013) Pathologic classification of adenocarcinoma of lung. J Surg Oncol 108(5):320–326

    Article  PubMed  Google Scholar 

  61. Travis WD, Brambilla E, Muller-Hermelink HK (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. IARC Press, Lyon

    Google Scholar 

  62. Chen R, Ding Z, Zhu L, Lu S, Yu Y (2017) Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. Eur J Surg Oncol 43(12):2308–2314

    Article  PubMed  Google Scholar 

  63. Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW et al (2014) Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 9(8):1126–1139

    Article  PubMed  PubMed Central  Google Scholar 

  64. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC (2013) Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e278S–e313S

    Article  CAS  PubMed  Google Scholar 

  65. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI et al (2011) Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141(3):662–670

    Article  PubMed  PubMed Central  Google Scholar 

  66. Liang W, He J, Shen Y, Shen J, He Q, Zhang J et al (2017) Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry. J Clin Oncol 35(11):1162–1170

    Article  PubMed  Google Scholar 

  67. Tantraworasin A, Saeteng S, Siwachat S, Jiarawasupornchai T, Lertprasertsuke N, Kongkarnka S et al (2017) Impact of lymph node management on resectable non-small cell lung cancer patients. J Thorac Dis 9(3):666–674

    Article  PubMed  PubMed Central  Google Scholar 

  68. Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T et al (2017) A randomized phase III trial of lobe-specific vs. systematic nodal dissection for clinical stage I-II non-small cell lung cancer (JCOG1413). Jpn J Clin Oncol 48:1–5

    Google Scholar 

  69. Vannucci F, Gonzalez-Rivas D (2016) Is VATS lobectomy standard of care for operable non-small cell lung cancer? Lung Cancer 100:114–119

    Article  PubMed  Google Scholar 

  70. Veronesi G (2013) Robotic surgery for the treatment of early-stage lung cancer. Curr Opin Oncol 25(2):107–114

    Article  PubMed  Google Scholar 

  71. Heo W, Kang DK, Min HK, Jun HJ, Hwang YH (2017) Feasibility and safety of single-port video-assisted thoracic surgery for primary lung cancer. Korean J Thorac Cardiovasc Surg 50(3):190–196

    Article  PubMed  PubMed Central  Google Scholar 

  72. Mazzone P (2012) Preoperative evaluation of the lung resection candidate. Cleve Clin J Med 79(Electronic Suppl 1):eS17–eS22

    PubMed  Google Scholar 

  73. Dziedzic R, Zurek W, Marjanski T, Rudzinski P, Orlowski TM, Sawicka W et al (2017) Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg 52(2):363–369

    Article  PubMed  Google Scholar 

  74. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374(9687):379–386

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Guo SX, Jian Y, Chen YL, Cai Y, Zhang QY, Tou FF (2016) Neoadjuvant chemoradiotherapy vesus chemotherapy alone followed by surgery for resectable stage III non-small-cell lung cancer: a meta-analysis. Sci Rep 6:34388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kim AW, Boffa DJ, Wang Z, Detterbeck FC (2012) An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg 143(1):55–63

    Article  PubMed  Google Scholar 

  77. Donington JS, Pass HI (2014) Surgical resection of non-small cell lung cancer with N2 disease. Thorac Surg Clin 24(4):449–456

    Article  PubMed  Google Scholar 

  78. Evans NR 3rd, Li S, Wright CD, Allen MS, Gaissert HA (2010) The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. J Thorac Cardiovasc Surg 139(4):991–9916 e2

    Article  PubMed  Google Scholar 

  79. Kamel MK, Nasar A, Stiles BM, Altorki NK, Port JL (2017) Video-assisted thoracoscopic lobectomy is the preferred approach following induction chemotherapy. J Laparoendosc Adv Surg Tech A 27(5):495–500

    Article  PubMed  Google Scholar 

  80. Yang CF, Meyerhoff RR, Mayne NR, Singhapricha T, Toomey CB, Speicher PJ et al (2016) Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. Eur J Cardiothorac Surg 49(6):1615–1623

    Article  PubMed  Google Scholar 

  81. Mehran R (2013) The role of surgery in patients with clinical n2 disease. Thorac Surg Clin 23(3):327–335

    Article  PubMed  Google Scholar 

  82. Obiols C, Call S, Rami-Porta R, Trujillo-Reyes JC, Saumench R, Iglesias M et al (2013) Survival of patients with unsuspected pN2 non-small cell lung cancer after an accurate preoperative mediastinal staging. Ann Thorac Surg 97(3):957–964

    Article  PubMed  Google Scholar 

  83. Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e314S–e340S

    Article  CAS  PubMed  Google Scholar 

  84. d’Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM et al (2009) Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 88(4):1079–1085

    Article  PubMed  Google Scholar 

  85. Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z (2015) Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. Med Sci Monit 21:144–152

    Article  PubMed  PubMed Central  Google Scholar 

  86. Yuksel C, Bozkurt M, Yenigun BM, Enon S, Ozkan M, Kose SK et al (2013) The outcome of bifocal surgical resection in non-small cell lung cancer with synchronous brain metastases: results of a single center retrospective study. Thorac Cardiovasc Surg 62(7):605–611

    Article  PubMed  Google Scholar 

  87. Yang SY, Kim DG, Lee SH, Chung HT, Paek SH, Hyun Kim J et al (2008) Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer 112(8):1780–1786

    Article  PubMed  Google Scholar 

  88. Kong DS, Lee JI, Nam DH, Park K, Kim JH, Kim JG et al (2006) Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci 21(3):527–532

    Article  PubMed  PubMed Central  Google Scholar 

  89. Choi JW, Kong DS, Seol HJ, Nam DH, Yoo KH, Sun JM et al (2016) Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non-small cell lung cancer. World Neurosurg 95:399–405

    Article  PubMed  Google Scholar 

  90. Yu XJ, Dai WR, Xu Y (2017) Survival outcome after stereotactic body radiation therapy and surgery for early stage non-small cell lung cancer: a meta-analysis. J Investig Surg 31:1–8

    Google Scholar 

  91. Schneider BJ, Daly ME, Kennedy EB, Stiles BM (2017) Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based guideline summary. J Oncol Pract. https://doi.org/10.1200/JOP.2017.028894

  92. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559

    Article  PubMed  Google Scholar 

  93. Herskovic A, Mauer E, Christos P, Nagar H (2017) Role of postoperative radiotherapy in pathologic stage IIIA (N2) non-small cell lung cancer in a prospective Nationwide oncology outcomes database. J Thorac Oncol 12(2):302–313

    Article  PubMed  Google Scholar 

  94. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452–1460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929

    Article  CAS  PubMed  Google Scholar 

  97. Zhang XN, Huang L (2017) Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials. Oncotarget 8(52):90327–90337

    PubMed  PubMed Central  Google Scholar 

  98. Felip E, Rosell R, Maestre JA, Rodriguez-Paniagua JM, Moran T, Astudillo J et al (2010) Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 28(19):3138–3145

    Article  CAS  PubMed  Google Scholar 

  99. NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26(28):4617–4625

    Article  PubMed Central  Google Scholar 

  100. Schrump DS, Carter D, Kelsey CR (2011) Non-small cell lung cancer in cancer. In: Principles & practice of oncology, 9th edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  101. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98

    Article  CAS  PubMed  Google Scholar 

  102. Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M et al (2017) Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer 83:302–312

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Saad AS, Ghali RR, Shawki MA (2017) A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer. J Cancer Res Ther 13(2):198–203

    Article  CAS  PubMed  Google Scholar 

  104. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551

    Article  CAS  PubMed  Google Scholar 

  105. Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS et al (2017) Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL Trial. Clin Lung Cancer 18(4):e289–ee96

    Article  CAS  PubMed  Google Scholar 

  106. Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN et al (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31(23):2849–2853

    Article  CAS  PubMed  Google Scholar 

  107. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957

    Article  CAS  PubMed  Google Scholar 

  108. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246

    Article  CAS  PubMed  Google Scholar 

  109. Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY et al (2017) A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer 116(5):568–574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334

    Article  CAS  PubMed  Google Scholar 

  111. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2017) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

    Article  PubMed  Google Scholar 

  112. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629–640

    Article  CAS  PubMed  Google Scholar 

  113. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ (2012) Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17(11):1351–1375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E et al (2015) FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 21(11):2436–2439

    Article  CAS  PubMed  Google Scholar 

  116. Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G et al (2016) FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following Crizotinib. Clin Cancer Res 22(21):5171–5176

    Article  CAS  PubMed  Google Scholar 

  117. Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J et al (2016) The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res 22(22):5527–5538

    Article  CAS  PubMed  Google Scholar 

  118. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389(10072):917–929

    Article  CAS  PubMed  Google Scholar 

  119. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829–838

    Article  CAS  PubMed  Google Scholar 

  120. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW et al (2017) Brigatinib in patients with Crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II Trial. J Clin Oncol 35(22):2490–2498

    Article  CAS  PubMed  Google Scholar 

  121. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A et al (2016) Resensitization to Crizotinib by the Lorlatinib ALK resistance mutation L1198F. N Engl J Med 374(1):54–61

    Article  CAS  PubMed  Google Scholar 

  122. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531

    Article  CAS  PubMed  Google Scholar 

  123. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28(6):911–917

    Article  CAS  PubMed  Google Scholar 

  124. Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774

    Article  CAS  PubMed  Google Scholar 

  125. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH et al (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24(1):20–30

    Article  PubMed  Google Scholar 

  126. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J et al (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29(8):1067–1074

    Article  CAS  PubMed  Google Scholar 

  127. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440

    Article  CAS  PubMed  Google Scholar 

  128. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–529

    Article  CAS  PubMed  Google Scholar 

  129. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550

    Article  CAS  PubMed  Google Scholar 

  130. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31(23):2895–2902

    Article  CAS  PubMed  Google Scholar 

  131. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27(4):591–598

    Article  CAS  PubMed  Google Scholar 

  132. Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V et al (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30(28):3516–3524

    Article  CAS  PubMed  Google Scholar 

  133. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH et al (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31(24):3004–3011

    Article  CAS  PubMed  Google Scholar 

  134. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354–2362

    Article  CAS  PubMed  Google Scholar 

  135. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10):2095–2103

    Article  CAS  PubMed  Google Scholar 

  136. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597

    Article  CAS  PubMed  Google Scholar 

  137. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27(11):1836–1843

    Article  CAS  PubMed  Google Scholar 

  138. Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D et al (2017) Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer 112:181–187

    Article  PubMed  Google Scholar 

  139. Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143–155

    Article  CAS  PubMed  Google Scholar 

  140. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673

    Article  CAS  PubMed  Google Scholar 

  141. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132

    Article  CAS  PubMed  Google Scholar 

  142. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818

    Article  CAS  PubMed  Google Scholar 

  143. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catala Ferrer M, Bravo I, Mendoza del Pino M et al (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26(9):1452–1458

    Article  CAS  PubMed  Google Scholar 

  144. Stanford JL, Stanford CA, O’Brien ME, Grange JM (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44(2):224–227

    Article  CAS  PubMed  Google Scholar 

  145. Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P et al (2004) Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96(4):326–331

    Article  CAS  PubMed  Google Scholar 

  146. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J et al (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24(29):4721–4730

    Article  CAS  PubMed  Google Scholar 

  147. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23(27):6674–6681

    Article  CAS  PubMed  Google Scholar 

  148. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W et al (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31(19):2396–2403

    Article  CAS  PubMed  Google Scholar 

  149. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A et al (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12(12):1125–1133

    Article  CAS  PubMed  Google Scholar 

  150. Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F et al (2017) Phase III trial of Ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 35(30):3449–3457

    Article  CAS  PubMed  Google Scholar 

  151. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41

    Article  CAS  PubMed  Google Scholar 

  152. Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF (2000) Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 47(1):149–155

    Article  CAS  PubMed  Google Scholar 

  153. Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK (2006) The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review. Brachytherapy 5(3):189–202

    Article  PubMed  Google Scholar 

  154. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT et al (2013) Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e211S–ee50S

    Article  PubMed  Google Scholar 

  155. Zielinski M, Szlubowski A, Kolodziej M, Orzechowski S, Laczynska E, Pankowski J et al (2013) Comparison of endobronchial ultrasound and/or endoesophageal ultrasound with transcervical extended mediastinal lymphadenectomy for staging and restaging of non-small-cell lung cancer. J Thorac Oncol 8(5):630–636

    Article  PubMed  Google Scholar 

  156. Labarca G, Aravena C, Ortega F, Arenas A, Majid A, Folch E et al (2016) Minimally invasive methods for staging in lung cancer: systematic review and meta-analysis. Pulm Med 2016:1024709

    Article  PubMed  PubMed Central  Google Scholar 

  157. Park SY, Kim BH, Kim JH, Lee S, Kang GH (2007) Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 131(10):1561–1567

    CAS  PubMed  Google Scholar 

  158. Cetinkaya E, Usluer O, Yilmaz A, Tutar N, Cam E, Ozgul MA et al (2017) Is endobronchial ultrasound-guided transbronchial needle aspiration an effective diagnostic procedure in restaging of non-small cell lung cancer patients? Endosc Ultrasound 6(3):162–167

    Article  PubMed  PubMed Central  Google Scholar 

  159. Nasir BS, Bryant AS, Minnich DJ, Wei B, Dransfield MT, Cerfolio RJ (2014) The efficacy of restaging endobronchial ultrasound in patients with non-small cell lung cancer after preoperative therapy. Ann Thorac Surg 98(3):1008–1012

    Article  PubMed  Google Scholar 

  160. Genestreti G, Burgio MA, Matteucci F, Piciucchi S, Scarpi E, Monti M et al (2015) Endobronchial/endoesophageal ultrasound (EBUS/EUS) guided fine needle aspiration (FNA) and 18F-FDG PET/CT scanning in restaging of locally advanced non-small cell lung cancer (NSCLC) treated with chemo-radiotherapy: a mono-institutional pilot experience. Technol Cancer Res Treat 14(6):721–727

    Article  CAS  PubMed  Google Scholar 

  161. von Bartheld MB, Versteegh MI, Braun J, Willems LN, Rabe KF, Annema JT (2011) Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer. J Thorac Oncol 6(9):1510–1515

    Article  Google Scholar 

  162. De Waele M, Hendriks J, Lauwers P, Hertoghs M, Carp L, Salgado R et al (2011) Restaging the mediastinum in non-small cell lung cancer after induction therapy: non-invasive versus invasive procedures. Acta Chir Belg 111(3):161–164

    Article  PubMed  Google Scholar 

  163. de Cabanyes CS, Detterbeck FC (2010) A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 5(3):389–398

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Apichat Tantraworasin, Somcharoen Saeteng & Sophon Siwachat

  2. Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Sarawut Kongkarnka & Nirush Lertprasertsuke

  3. Department of Radiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Yutthaphan Wannasopha & Juntima Euathrongchit

  4. Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Thatthan Suksombooncharoen & Busayamas Chewaskulyong

Authors
  1. Apichat Tantraworasin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarawut Kongkarnka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nirush Lertprasertsuke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yutthaphan Wannasopha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juntima Euathrongchit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thatthan Suksombooncharoen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Somcharoen Saeteng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sophon Siwachat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Busayamas Chewaskulyong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Apichat Tantraworasin .

Editor information

Editors and Affiliations

  1. Division of Medical Oncology, Federal University of São Paulo (UNIFESP) & Hospital Israelita Albert Einstein, São Paulo, Brazil, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal

    Ramon Andrade De Mello

  2. Oncology Department, Henry Dunant Hospital Center, Athens, Greece

    Giannis Mountzios

  3. Department of Biomedical Sciences and Medicine, Universidade do Algarve, Faro, Portugal

    Álvaro A. Tavares

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tantraworasin, A. et al. (2019). Non-small Cell Lung Cancer. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_9

Download citation

Publish with us

Policies and ethics

Search

Navigation